CN113929683A - Method for improving bulk density and fluidity of riboflavin crystals - Google Patents
Method for improving bulk density and fluidity of riboflavin crystals Download PDFInfo
- Publication number
- CN113929683A CN113929683A CN202111352603.4A CN202111352603A CN113929683A CN 113929683 A CN113929683 A CN 113929683A CN 202111352603 A CN202111352603 A CN 202111352603A CN 113929683 A CN113929683 A CN 113929683A
- Authority
- CN
- China
- Prior art keywords
- riboflavin
- crystals
- hydrochloric acid
- product
- mass fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims abstract description 170
- 239000002151 riboflavin Substances 0.000 title claims abstract description 85
- 235000019192 riboflavin Nutrition 0.000 title claims abstract description 85
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 229960002477 riboflavin Drugs 0.000 title claims abstract description 84
- 239000013078 crystal Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000000243 solution Substances 0.000 claims abstract description 53
- 239000012047 saturated solution Substances 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000012535 impurity Substances 0.000 claims abstract description 12
- 238000001816 cooling Methods 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 42
- 238000001035 drying Methods 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000010791 quenching Methods 0.000 claims description 7
- 230000000171 quenching effect Effects 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 10
- 239000012296 anti-solvent Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 238000004321 preservation Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102100021202 Desmocollin-1 Human genes 0.000 description 2
- 101000968043 Homo sapiens Desmocollin-1 Proteins 0.000 description 2
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000020939 nutritional additive Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- -1 riboflavin monohydrate Chemical class 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
- C07D475/14—Benz [g] pteridines, e.g. riboflavin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method for improving the bulk density and the flowability of riboflavin crystals, which comprises the following steps: (1) dissolving a riboflavin sample into a hydrochloric acid solution with the mass fraction of 27-31%, and carrying out solid-liquid separation to obtain a saturated solution; (2) adding the saturated solution obtained in the step (1) into a hydrochloric acid solution with the mass fraction of 1.4% -2.4%, mixing, cooling and growing crystals to obtain riboflavin crystals; the riboflavin product obtained by the method is rod-shaped, has good fluidity, the bulk density of the product reaches 0.50g/mL-0.88g/mL, and the single impurity content of the product is less than 0.2%.
Description
Technical Field
The invention belongs to the technical field of medical crystallization, and relates to a method for improving the bulk density and the flowability of riboflavin crystals.
Background
Riboflavin, alias vitamin B2Is an important component of vitamin B group, the precursor of which is vitamin G and the molecular formula of which is C17H20N4O6Molecular weight 376.37, chemical name 7, 8-dimethyl-10 (1' -D-ribityl) -isoalloxazine, respectively.
Riboflavin exerts biological effects in vivo in the form of flavin coenzymes, and mainly takes part in various redox reactions in vivo in the form of flavin mononucleotide and flavin adenine dinucleotide. Lack of riboflavin can cause fatigue, hypodynamia and itching eyes with burning sensation, and the pathological changes of oral cavity and scrotum appear, which is called oral cavity reproductive system syndrome and is a common nutritional deficiency disease for residents in China. In addition, research shows that the riboflavin has the effects of promoting urination, preventing cancer, reducing blood pressure, improving cardiac function and the like. The American food nutrition Committee recommends that the daily intake dose of riboflavin for adults is 0.9-1.3 mg. It is not only widely used in clinical applications, but also, because it is non-toxic and yellow in color, it is often used in the food industry as a nutritional additive and a pigment. Riboflavin is one of the early vitamins entering the international market, more than two hundred clinical application, health care and anti-aging preparations are used at home and abroad, and the demand of the market for the riboflavin is continuously increased due to the rapid development of the food industry, the health care product industry and the nutritional additive industry.
Most of riboflavin crystals are needle-shaped at present, and due to the small bulk density and poor flow property, the processing property is poor, the processing difficulty is high, and the processing properties such as tabletting and the like are influenced finally. In the prior art, methods for separating and purifying riboflavin exist, for example, CN109851619A discloses a riboflavin purification process, which uses an acid dissolution method to perform crystallization to purify a riboflavin product, but the obtained riboflavin product has low bulk density, and metal powder, inorganic salt and a small-molecule reducing organic reagent are added as reducing agents in the process, so that the subsequent post-treatment problem exists. Patent CN110283175A discloses a preparation process of high-purity riboflavin, which comprises dissolving crude riboflavin in acid or alkali, taking filtrate, crystallizing and drying to obtain riboflavin product, but the problem of overdimension of impurity a and impurity D in riboflavin product is easily caused due to the alkali dissolution method used in the process. Patent CN1765897A discloses an extraction process of riboflavin fermentation broth, comprising the steps of pretreatment of fermentation broth, membrane filtration, acidification, oxidation and crystallization, and recovering riboflavin in the acidified mother liquor by a recovery process. The method has low riboflavin content and yield.
In view of the above, the application of riboflavin in the fields of medicine and the like is widened, and the application problem of riboflavin at present is overcome.
Therefore, it is of great importance to develop a high quality riboflavin product with high bulk density, good fluidity and high purity.
Disclosure of Invention
The invention aims to provide a method for improving the bulk density and the fluidity of riboflavin products, wherein the riboflavin products prepared by the preparation method are rod-shaped in crystal habit and good in fluidity, the bulk density of the products reaches 0.50-0.88g/mL, and the single impurity content of the products is less than 0.2%.
In order to achieve the purpose, the invention adopts the following technical scheme:
one of the objects of the present invention is to provide a method for increasing the bulk density and fluidity of riboflavin crystals, said method comprising the steps of:
(1) dissolving a riboflavin sample into a hydrochloric acid solution with the mass fraction of 27-31%, and carrying out solid-liquid separation to obtain a saturated solution;
(2) and (2) adding the saturated solution obtained in the step (1) into a hydrochloric acid solution with the mass fraction of 1.4% -2.4%, mixing, cooling and growing crystals to obtain riboflavin crystals.
Preferably, the riboflavin sample in the step (1) is riboflavin crude product or purified riboflavin crude product.
Preferably, the preparation method of the purified crude riboflavin comprises the following steps: dissolving the crude riboflavin product into a hydrochloric acid solution with the mass fraction of 1.4-7.5%, or dissolving the crude riboflavin product in water and suspending for 4-5h at the temperature of 80-90 ℃.
Preferably, the riboflavin sample in step (1) has a dissolution temperature of 30-50 ℃.
Preferably, the solid-liquid separation method in the step (1) is filtration.
Preferably, the saturated solution in the step (2) is added dropwise at a rate of 0.5-1 mL/min.
Preferably, the mixing temperature in step (2) is 60-80 ℃.
Preferably, the volume ratio of the saturated solution in the step (2) to the hydrochloric acid solution with the mass fraction of 1.4% -2.4% is (0.16-0.19) to 1.
Preferably, the cooling temperature in step (2) is 5-40 ℃.
Preferably, the cooling rate of step (2) is not less than 5 mL/min.
Preferably, the time for growing the crystals in the step (2) is 0-2 h.
Preferably, the step (2) further comprises: and sequentially washing, carrying out solid-liquid separation and drying on the product obtained after cooling.
Preferably, the solid-liquid separation mode is filtration.
Preferably, the drying is carried out under normal pressure, the drying temperature is 60-90 ℃, and the drying time is 12-24 h.
As a preferred technical scheme of the invention, the method comprises the following steps:
(1) putting the riboflavin crude product or the purified riboflavin crude product into hydrochloric acid solution with the mass fraction of 27-31%, dissolving at 30-50 ℃, and filtering to obtain riboflavin filtrate;
(2) heating the riboflavin filtrate obtained in the step (1) to 60-80 ℃, and dropwise adding the riboflavin filtrate into a hydrochloric acid solution with the mass fraction of 1.4% -2.4% at the dropwise adding rate of 0.5-1mL/min to obtain a quenching front liquid;
(3) cooling the pre-quenching liquid obtained in the step (2) to 5-40 ℃ at a quenching rate of not less than 5mL/min to precipitate crystals, and growing the crystals for 0-2h to obtain a mixture;
(4) and (4) filtering the mixture obtained in the step (3), and drying at 60-90 ℃ for 12-24h under normal pressure to obtain riboflavin crystals.
The second object of the present invention is to obtain riboflavin crystals prepared by the process according to the first object.
Preferably, the bulk density of the riboflavin crystals is 0.50-0.88g/mL, and the product impurity is less than 0.2%.
The third object of the present invention is to provide a riboflavin crystal according to the second object for use in the preparation of a medicament or a dietary supplement.
Compared with the prior art, the invention has the following beneficial effects:
the riboflavin product prepared by the method provided by the invention is rod-shaped in crystal habit and good in fluidity, the bulk density of the product reaches 0.50-0.88g/mL, and the single impurity content of the product is less than 0.2%.
Drawings
FIG. 1 is a microscopic image of riboflavin obtained in example 1;
FIG. 2 is a PXRD spectrum of riboflavin prepared in example 1;
FIG. 3 is a TG plot of riboflavin prepared in example 1;
FIG. 4 is a DSC of riboflavin obtained in example 1.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
A2.4% hydrochloric acid solution was prepared, and 240mL of the solution was added to a main stirred crystallizer and incubated at 60 ℃. Weighing 10g of crude raw material of the unpurified riboflavin, dissolving the crude raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, adding 45mL of supernatant into a crystallizer, stirring with a main stirrer for series connection and heat preservation, dropping the saturated solution into an anti-solvent in a positive direction, allowing the solution to be used, directly pouring the dropped solution into the crystallizer at 5 ℃, growing the crystal for 2h after the crystal is generated, and after the completion, washing, drying and waiting for performance detection.
FIG. 1 is a micrograph of riboflavin obtained in example 1 (type: OLYMPUS, BX53, Japan), and it can be seen from FIG. 1 that the crystals of the product had a rod shape.
FIG. 2 is an XRD pattern (model D/MAX-2500, Japan) of the product obtained in example 1, and it can be seen from FIG. 2 that the product is riboflavin monohydrate.
FIG. 3 is a TG graph (model number Mettler Toledo, TGA/DSC1/SF) of the product obtained in example 1, and it can be seen from FIG. 3 that the weight loss of water is present before 100 ℃.
FIG. 4 shows the DSC of the product obtained in example 1 (model Mettler-Toledo, DSC1/500, Switzerland), from FIG. 4 it can be seen that there are two exothermic peaks, one at 100 ℃ for the loss of water.
Carry out performance test to gained product, weigh the product m of certain quality, place the solid in the graduated flask, the graduated flask of vibration makes the sample compact repeatedly, and the back-off does not have the solid to drop, records product volume V, and bulk density equals m/V and knows: the bulk density of the product obtained in example 1 was 0.50 g/mL.
And (3) performing impurity measurement on the obtained product, and adopting a high performance liquid chromatography according to European pharmacopoeia to obtain the product with single impurity less than 0.2%.
Example 2
A2.4% hydrochloric acid solution was prepared, 240mL of the solution was added to the main stirred crystallizer and the temperature was maintained at 70 ℃. Weighing 10g of crude raw material of the unpurified riboflavin, dissolving the crude raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, adding 45mL of supernatant into a crystallizer, stirring with a main stirrer to carry out series connection and heat preservation, dropping the saturated solution into an anti-solvent in a positive direction, allowing the solution to be used, directly pouring the dropped solution into the crystallizer at 15 ℃, growing the crystals for 2h after the crystals are generated, and after the completion, washing, drying and detecting the performance.
The same test method as in example 1 was used to test the performance of the product, and it was found that: the bulk density is 0.56g/mL, and the single impurity of the obtained product is less than 0.2 percent.
Example 3
A2.4% hydrochloric acid solution was prepared, 240mL of the solution was added to the main stirred crystallizer and the temperature was maintained at 70 ℃. Weighing 5g of crude raw material purified by riboflavin 2.4% hydrochloric acid, dissolving the raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, adding 45mL of supernatant into a crystallizer, stirring with a main stirrer for series connection and heat preservation, dropping saturated solution into an antisolvent in a positive direction, allowing the solution to be used, directly pouring the dropped solution into the crystallizer at 30 ℃, growing crystals for 2h after the crystals are formed, and after the completion, washing, drying and waiting for performance detection.
The same test method as in example 1 was used to test the performance of the product, and it was found that: the bulk density is 0.61g/mL, and the single impurity of the obtained product is less than 0.2 percent.
Example 4
A2.4% hydrochloric acid solution was prepared, 240mL of the solution was added to the main stirred crystallizer and the temperature was maintained at 70 ℃. Weighing 5g of crude raw material purified by riboflavin 2.4% hydrochloric acid, dissolving the raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, adding 45mL of supernatant into a crystallizer, stirring with a main stirrer for series connection and heat preservation, dropping saturated solution into an antisolvent in a positive direction, allowing the solution to be used, directly pouring the dropped solution into the crystallizer at 40 ℃, growing crystals for 2h after the crystals are formed, and after the completion, washing, drying and waiting for performance detection.
The same test method as in example 1 was used to test the performance of the product, and it was found that: the bulk density is 0.63g/mL, and the single impurity of the obtained product is less than 0.2 percent.
Example 5
A2.4% hydrochloric acid solution was prepared, 240mL of the solution was added to the main stirred crystallizer and the temperature was maintained at 70 ℃. Weighing 5g of crude raw material after riboflavin purification, dissolving the crude raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, adding 45mL of supernatant into a crystallizer, stirring with a main stirrer to carry out series connection and heat preservation, dropping saturated solution into an anti-solvent in a positive direction, allowing the solution to be used, directly pouring the dropped solution into the crystallizer at 15 ℃, growing crystals for 2h after crystal growth, and after finishing, washing, drying and waiting for performance detection.
The same test method as in example 1 was used to test the performance of the product, and it was found that: the bulk density is 0.88g/mL, and the single impurity of the obtained product is less than 0.2 percent.
Comparative example 1
The only difference from example 1 is that the temperature decrease rate was controlled at 4 deg.C/min.
A2.4% hydrochloric acid solution was prepared, 240mL of the solution was added to the main stirred crystallizer and the temperature was maintained at 70 ℃. Weighing 5g of crude raw material after riboflavin purification, dissolving the crude raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, adding 45mL of supernatant into a crystallizer, stirring with a main stirrer for series connection and heat preservation, dropping saturated solution into an anti-solvent in a positive direction, standing the solution, controlling the temperature reduction rate of the dropped solution at 4 ℃/min, growing crystals for 2h after crystal growth, and after finishing, washing, drying and waiting for performance detection.
The same test method as in example 1 was used to test the performance of the product, and it was found that: the bulk density was 0.22 g/mL.
It is understood from a comparison between example 1 and comparative example 1 that a decrease in the temperature decrease rate increases the crystal aspect ratio and decreases the bulk density.
Comparative example 2
The difference from example 1 is only that the preparation method is the same as example 1 except that the addition of 2.4 mass percent hydrochloric acid solution is not included.
Weighing 10g of crude raw material of the unpurified riboflavin, dissolving the crude raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, taking 45mL of supernatant, adding the supernatant into a crystallizer, keeping the temperature at 60 ℃, standing the solution for later use, directly pouring the heat-kept solution into the crystallizer with the temperature of 5 ℃, wherein no crystal is separated out because the solubility under the concentration of 31% hydrochloric acid is too high and the saturation caused by the temperature is not enough for nucleation.
It is clear from a comparison of example 1 and comparative example 2 that the necessity of adding an anti-solvent for crystallization does not allow crystals to precipitate when a quenching experiment is carried out after dissolution with a high mass fraction of hydrochloric acid as it is.
Comparative example 3
The only difference from example 1 is that the hydrochloric acid solution having a mass fraction of 2.4% was replaced with a hydrochloric acid solution having a mass fraction of 0%, and the remaining preparation method was the same as in example 1.
240mL of a 0% solution of hydrochloric acid was added to the main stirred crystallizer and incubated at 60 ℃. Weighing 10g of crude raw material of the unpurified riboflavin, dissolving the crude raw material in 50mL of hydrochloric acid solution with the mass fraction of 31% at 50 ℃, suspending for 30min, taking 45mL of supernatant, adding the supernatant into a crystallizer, stirring with a main stirrer to carry out series connection and heat preservation, dropping the saturated solution into an anti-solvent in a positive direction, directly separating out crystals in the dissolution process, growing the crystals for 2h after the crystals are separated out, and after the crystals are separated out, washing, drying and detecting the performance.
The same test method as in example 1 was used to test the performance of the product, and it was found that: the bulk density was 0.30 g/mL.
It is understood from the comparison between example 1 and comparative example 3 that the decrease in the mass fraction of hydrochloric acid causes crystals having a relatively large major axis to be directly precipitated in the elution process, and the bulk density is reduced.
Claims (10)
1. A method for increasing the bulk density and flowability of riboflavin crystals, said method comprising the steps of:
(1) dissolving a riboflavin sample into a hydrochloric acid solution with the mass fraction of 27-31%, and carrying out solid-liquid separation to obtain a saturated solution;
(2) and (2) adding the saturated solution obtained in the step (1) into a hydrochloric acid solution with the mass fraction of 1.4% -2.4%, mixing, cooling and growing crystals to obtain riboflavin crystals.
2. The method according to claim 1, wherein the riboflavin sample of step (1) is crude riboflavin or purified crude riboflavin;
preferably, the preparation method of the purified crude riboflavin comprises the following steps: dissolving the crude riboflavin product into a hydrochloric acid solution with the mass fraction of 1.4-7.5%, or dissolving the crude riboflavin product in water and suspending for 4-5h at the temperature of 80-90 ℃.
3. The method according to claim 1, wherein the riboflavin sample in the step (1) has a dissolution temperature of 30-50 ℃;
preferably, the solid-liquid separation method in the step (1) is filtration.
4. The method according to claim 1, wherein the saturated solution in the step (2) is added dropwise at a rate of 0.5-1 mL/min;
preferably, the mixing temperature in step (2) is 60-80 ℃.
5. The method as claimed in claim 1, wherein the volume ratio of the saturated solution to the hydrochloric acid solution with the mass fraction of 1.4% -2.4% in the step (2) is (0.16-0.19): 1.
6. The method of claim 1, wherein the cooling temperature of step (2) is 5-40 ℃;
preferably, the cooling rate of step (2) is not less than 5 mL/min;
preferably, the time for growing the crystals in the step (2) is 0-2 h.
7. The method of claim 1, wherein step (2) further comprises: washing, solid-liquid separation and drying are sequentially carried out on the product obtained after cooling;
preferably, the solid-liquid separation mode is filtration;
preferably, the drying is carried out under normal pressure, the drying temperature is 60-90 ℃, and the drying time is 12-24 h.
8. Method according to claim 1, characterized in that it comprises the following steps:
(1) putting the riboflavin crude product or the purified riboflavin crude product into hydrochloric acid solution with the mass fraction of 27-31%, dissolving at 30-50 ℃, and filtering to obtain riboflavin filtrate;
(2) heating the riboflavin filtrate obtained in the step (1) to 60-80 ℃, and dropwise adding the riboflavin filtrate into a hydrochloric acid solution with the mass fraction of 1.4% -2.4% at the dropwise adding rate of 0.5-1mL/min to obtain a quenching front liquid;
(3) cooling the pre-quenching liquid obtained in the step (2) to 5-40 ℃ at a quenching rate of not less than 5mL/min to precipitate crystals, and growing the crystals for 0-2h to obtain a mixture;
(4) and (4) filtering the mixture obtained in the step (3), and drying at 60-90 ℃ for 12-24h under normal pressure to obtain riboflavin crystals.
9. Riboflavin crystals obtained by the process according to any one of claims 1 to 8;
preferably, the bulk density of the riboflavin crystals is 0.50-0.88g/mL, and the product impurity is less than 0.2%.
10. The riboflavin crystals according to claim 9 for use in the preparation of a medicament or a food additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111352603.4A CN113929683A (en) | 2021-11-15 | 2021-11-15 | Method for improving bulk density and fluidity of riboflavin crystals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111352603.4A CN113929683A (en) | 2021-11-15 | 2021-11-15 | Method for improving bulk density and fluidity of riboflavin crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113929683A true CN113929683A (en) | 2022-01-14 |
Family
ID=79286697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111352603.4A Pending CN113929683A (en) | 2021-11-15 | 2021-11-15 | Method for improving bulk density and fluidity of riboflavin crystals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113929683A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1774438A (en) * | 2003-04-11 | 2006-05-17 | 巴斯福股份公司 | Method for the production of riboflavin of modification B/C in granular form |
| US20060240112A1 (en) * | 2003-07-22 | 2006-10-26 | Arnold Gloor | Process for the purification of riboflavin |
| CN109851619A (en) * | 2019-02-02 | 2019-06-07 | 赤峰制药股份有限公司 | A kind of riboflavin purifying technique |
-
2021
- 2021-11-15 CN CN202111352603.4A patent/CN113929683A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1774438A (en) * | 2003-04-11 | 2006-05-17 | 巴斯福股份公司 | Method for the production of riboflavin of modification B/C in granular form |
| US20060240112A1 (en) * | 2003-07-22 | 2006-10-26 | Arnold Gloor | Process for the purification of riboflavin |
| CN109851619A (en) * | 2019-02-02 | 2019-06-07 | 赤峰制药股份有限公司 | A kind of riboflavin purifying technique |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7858128B2 (en) | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight | |
| WO2021022788A1 (en) | Composition of 5-fluorouracil and refining method therefor | |
| CN110818752B (en) | Process for producing lactitol | |
| CN101317850B (en) | Sucrose absorption inhibitor | |
| CN116096376A (en) | Sperm motility improving agent and sperm motility improving method | |
| WO2018014866A1 (en) | Crystal form of dapagliflozin intermediate and preparation method therefor | |
| CN102491918A (en) | Alanyl glutamine compound and preparation method thereof | |
| CN104926709A (en) | L-tryptophan refining method | |
| CN102603709B (en) | Thioctic acid compound and preparation method thereof | |
| CN113929683A (en) | Method for improving bulk density and fluidity of riboflavin crystals | |
| CN109096129A (en) | A kind of preparation method of L-carnitine-L-tartrate | |
| CN109628541A (en) | A kind of method of enzymatic clarification penicillin V salt | |
| CN102391259B (en) | Nifuratel compound and preparation method thereof | |
| CN115304517B (en) | Separation and purification method of probenecid sodium process impurities | |
| CN101787027B (en) | Preparation method of high-purity carbamazepine (CBZ)-valaciclovir | |
| CN106749226A (en) | A kind of preparation method of avatrombopag maleates crystal formation C | |
| CN108440569B (en) | Preparation method of ceftriaxone sodium spherical crystal | |
| CN102838656A (en) | Preparation method of L-alanyl-L-glutamine | |
| CN106565749B (en) | The method for promoting Cefamandole Nafate quality using three-dimensional column plate purification solvent | |
| CN114149477B (en) | Crystallization method of vitamin B12 crystal and product thereof | |
| CN112279817B (en) | Preparation method of high-purity pramipexole dihydrochloride | |
| CN102002077B (en) | Novel conjugate of sialic acid-zinc methionine, preparation process and application thereof | |
| CN108484448A (en) | The method of one pot process N- carbamylglutamic acids | |
| CN109734724B (en) | Crystallization method of piperacillin acid | |
| CN107501216B (en) | Novel synthesis method of high-stability bismuth citrate ranitidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |